紫杉醇联合CPT-11治疗中期胃癌的近期临床效果及不良反应  

Analysis of the short-term clinical efficacy and adverse reactions of paclitaxel combined with CPT-11 in the treatment of intermediate gastric cancer

作　　者：陈世超 CHEN Shichao(The Second People＇ s Hospital of Luohe,Henan,Luohe 462000,China)

机构地区：[1]漯河市第二人民医院,河南漯河462000

出　　处：《包头医学院学报》2018年第6期64-65,共2页Journal of Baotou Medical College

摘　　要：目的:研究紫杉醇联合伊立替康(CPT-11)治疗中期胃癌的近期临床效果及不良反应。方法:将105例中期胃癌患者按照入院时间的先后顺序分为对照组(52例)与观察组(53例),观察组采用紫杉醇联合CPT-11治疗、对照组采用紫杉醇治疗,对比两种治疗方法的效果。结果:观察组患者的治疗有效率为75.5%,高于对照组的63.5%(P<0.05);观察组患者不良反应发生率为11.3%,低于对照组的28.8%(P<0.05)。结论:在中期胃癌的治疗中联合使用紫杉醇与CPT-11,能够提高治疗的整体有效率并降低治疗过程中的不良反应,提高治疗的安全性。Objective：To study the short-term clinical efficacy and adverse reactions of paclitaxel combined with CPT-11 in the treatment ofintermediate gastric cancer. Methods：105 patients with intermediate gastric cancer were divided into the control group （n=52） and the observation group （n=53） according to the chronological order of hospitalization. The observation group was treated with paclitaxel combined with CPT-11 while the control group was treated with paclitaxel, with the clinical effects compared. Results：The effective rate of the observation group was75. 5 %, higher than that of the control group （63.5 %）（ P〈0.05）. The incidence rate of adverse reactions in the observation group was 11.3 %, lower than that of the control group （28.8 %）（P〈0.05）. Conclusion： Paclitaxel combined with CPT-11 in the treatment of intermediate gastric cancer can improve the overall efficiency and reduce the adverse reactions during the treatment, and improve the safety of the treatment.

关 键 词：中期胃癌 紫杉醇 伊立替康 

分 类 号：R735.2[医药卫生—肿瘤]